

1 **PREDICTORS OF MORTALITY AND CLINICAL CHARACTERISTICS AMONG**
2 **CARBAPENEM-RESISTANT OR CARBAPENEMASE-PRODUCING**
3 **ENTEROBACTERIACEAE BLOODSTREAM INFECTION IN SPANISH**
4 **CHILDREN**

5 **María Fátima Ara-Montojo¹, Luis Escosa-García PhD¹, Marina Alguacil², Nieves**
6 **Seara², Carlos Zozaya³, Diego Plaza⁴, Cristina Schuffelmann-Gutiérrez⁵, Ángela de la**
7 **Vega⁶, Carlota Fernández-Cambor⁷, Esther Ramos-Boluda⁸, María Pilar Romero-**
8 **Gómez², Guillermo Ruiz-Carrascoso PhD², Itsaso Losantos-García⁹, María José**
9 **Mellado-Peña PhD¹, Rosa Gómez-Gil².**

10 1. Paediatric Tropical and Infectious Diseases, Department of Paediatrics, Hospital
11 Universitario La Paz, Madrid, Spain.

12 2. Department of Microbiology, Hospital Universitario La Paz, Madrid, Spain.

13 3. Department of Neonatology, Hospital Universitario La Paz, Madrid, Spain.

14 4. Department of Paediatric Hematology and Oncology, Hospital Universitario La Paz,
15 Madrid, Spain.

16 5. Paediatric Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain.

17 6. Department of Hepatology and Liver Transplantation, Hospital Universitario La Paz,
18 Madrid, Spain.

19 7. Department of Nephrology and Kidney Transplantation, Hospital Universitario La Paz,
20 Madrid, Spain.

21 8. Paediatric Intestinal Rehabilitation and Bowel Transplantation, Hospital Universitario
22 La Paz, Madrid, Spain.

23 9. Department of Biostatistics, Hospital Universitario La Paz, Madrid, Spain.

24

25

26 **María Fátima Ara-Montojo and Luis Escosa-García contributed equally to this**
27 **article and both should be considered first author.**

28 **María Fátima Ara-Montojo.** Servicio de pediatría hospitalaria, enfermedades infecciosas
29 y tropicales. Hospital Universitario La Paz. Paseo de la Castellana 261, C.P. 28046.
30 Madrid, Spain.

31 Telephone number: 0034 917277479.

32 E-mail: fatiaramon@gmail.com

33 **Luis Escosa-García.** Servicio de pediatría hospitalaria, enfermedades infecciosas y
34 tropicales. Hospital Universitario La Paz. Paseo de la Castellana 261, C.P. 28046. Madrid,
35 Spain.

36 Telephone number: 0034 917277479.

37 E-mail: luisescosa1983@gmail.com

38 **Running title:** “Carbapenem-resistant or carbapenemase-producing Enterobacteriaceae
39 bloodstream infection in Spanish children”

40 **Funding:** This work was not economical supported by any institution.

41 **Transparency declarations:** None to declare.

42

43

44

45

46

47

48

49

50

51 **Synopsis**

52 **Background:** Carbapenem-resistant Enterobacteriaceae (CRE) are a growing problem in
53 pediatric population worldwide with high mortality rates (18.5-52%) in bloodstream
54 infection (BSI).

55 **Objectives:** The aim of this study is to evaluate predictors of 30-day mortality in CRE BSI
56 in a pediatric cohort.

57 **Methods:** Retrospective observational single-center study (December 2005 - August 2018)
58 was conducted. CRE BSI in children 0 to 16 years were included. Microbiological
59 identification (MALDI Biotyper) and antimicrobial susceptibility testing (Vitek2® and
60 MicroScan panel NBC44) according to current EUCAST breakpoints were performed.
61 PCR OXVIKP® was used to confirm carbapenemases genes (OXA-48, VIM, KPC,
62 NDM). Demographic characteristics, underlying diseases, source of bacteremia,
63 antimicrobial therapy and outcomes were collected from medical records. Survival analysis
64 to establish predictors of 30 day-mortality was performed.

65 **Results:** Thirty-eight cases were included, 76.3% hospital-acquired infections and 23.7%
66 related to healthcare. All patients had underlying comorbidity and 52.6% had received a
67 transplant. VIM-carbapenemase was the predominant mechanism (92%). Previous CRE
68 colonization or infection rate was 52.6%. Gut (26%) and vascular catheter (21%) were the
69 predominant sources of infection. Crude mortality within 30 days was 18.4% (7/38);
70 directly related 30-day mortality was 10.5%. Conditions associated with an increment in
71 30-day mortality were intensive care admission and inadequate empiric therapy ($p<0.05$).
72 Combination antibiotic targeted treatment and a low meropenem MIC were not related to
73 improved survival.

74 **Conclusions:** CRE BSI mortality rate is high. The most important factor related to 30-day
75 survival in our CRE BSI cohort in children was success in empiric treatment with at least
76 one active antibiotic.

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97 **Introduction**

98 Carbapenem-resistant Enterobacteriaceae (CRE) infections are a growing problem in
99 pediatric population worldwide. In recent years, an increment in the number of cases has
100 been reported in many countries.¹⁻² Some risk factors have been identified in previous
101 studies, including underlying comorbidity, immunosuppression, previous central venous
102 catheter, endotracheal intubation and prior antibiotic exposure.^{3,4}

103 CRE infections in children have been associated with high mortality rates, up to 52%,
104 probably due to delays in appropriate antibiotic therapy, lack of available active antibiotics
105 against CRE, underlying conditions and illness severity.⁵ Therefore, treatment of CRE
106 infections is a real challenge for clinicians and pediatric antibiotic pipeline is limited. Some
107 studies in adults suggested that carbapenem-containing combination therapy was
108 associated with improved survival in severe invasive infections due to CRE.^{6,7} Due to the
109 lack of studies in children, data to guide management has been extrapolated from adult
110 literature. Current recommendation in pediatrics is combination therapy of at least two
111 agents with in vitro activity in most scenarios, until more available data and experience
112 with newer betalactam agents.⁸⁻¹⁰ To improve management of CRE infections in pediatric
113 population it is necessary to evaluate if combination therapy is associated with lower
114 mortality rates than monotherapy for all scenarios.

115 The aim of this study is to evaluate risk factors for CRE bacteremia and independent
116 predictors of mortality (up to 30 days) related to the infection in a pediatric cohort.

117

118

119

120

121 **Patients and Methods**

122 *Study design*

123 A retrospective observational single-center study was conducted.

124 *Setting*

125 Hospital Universitario La Paz (HULP) Children's Hospital is a tertiary hospital with 256
126 hospitalization beds belonging to the Spanish Health National System, serving more than
127 45,000 children's emergency and more than 8,000 children's hospital admissions per year
128 in Northern Madrid (Spain). It has a 16-bed pediatric intensive care unit (PICU) and a 23-
129 bed neonatal intensive care unit (NICU), being the National Referral Hospital for pediatric
130 transplantation.

131 *Inclusion and exclusion criteria*

132 Episodes of bloodstream infection (BSI) in children 0 to 16 years of age that showed the
133 growth of CRE were included from December 2005 to August 2018. CRE isolate was
134 defined as any Enterobacteriaceae non-susceptible to meropenem (MIC > 8 mg/L),
135 imipenem (MIC > 2 mg/L) or ertapenem (MIC > 0.5 mg/L), or if carbapenemase
136 production was documented.¹¹ Polymicrobial bacteremia episodes were excluded.

137 *Variables and Data Collection*

138 We collected demographic characteristics, reason for admission and diagnosis, underlying
139 diseases, source of bacteremia, empirical and targeted antimicrobial therapy and outcomes
140 from medical records. Hospital's Microbiology department provided microbiological data.

141 *Definitions*

142 BSI was classified as hospital-acquired, community-acquired or healthcare-associated
143 (HCA) according to classic and modified CDC criteria. Episodes of community-acquired

144 bacteremia were further classified as healthcare-associated (HCA) if any of the following
145 criteria were present: ¹² 48-hours hospital admission during the previous 90 days, receipt of
146 hemodialysis, intravenous medication or home wound care in the previous 30 days or
147 residence in a nursing home or long-term care facility.

148 Classification as sepsis or septic shock was performed according to definitions of the
149 International Consensus Conference on Pediatric Sepsis. ¹³

150 The primary source of bacteremia was determined by the clinical presentation and/or by
151 the evidence of an identical strain cultured near to or on the same date as the onset of BSI
152 from other body site. To classify an infection as catheter-related BSI the 2009 Infectious
153 Diseases Society of America (IDSA) Guidelines criteria were used. ¹⁴ When the source of
154 bacteremia could not be identified, it was classified as primary bacteremia.

155 According to Hsu AJ et al. recommendations, antimicrobial therapy was considered
156 “microbiologically appropriate” if the patient received one active agent against the isolate
157 (MIC within the susceptible range) and “clinically adequate” if the patient received a
158 combination of two active antibiotics at a right dose and route according to source of
159 infection. ⁸ Use of imipenem or meropenem (MIC \leq 8 mcg/ml) was considered adequate if
160 high-dosed (25 mg/kg q6h for imipenem, 40 mg/kg over 3 hours q8h for meropenem),
161 adjusted to renal function, and associated with a second microbiologically active agent.

162 *Bacterial isolates and microbiological work-up*

163 Blood cultures were incubated in the Bactec automated blood culture device (BACTEC™,
164 Becton Dickinson, Franklin Lakes, NJ, USA) and BacT/ALERT® (bioMérieux, Marcy
165 l’Etoile, France) blood culture bottle systems. All positive blood cultures were routinely
166 subcultivated on three agar plates: sheep blood agar, chocolate blood agar and *Brucella*
167 blood agar.

168 Identification was performed by MALDI Biotyper (Bruker Daltonik GmbH, Bremen,
169 Germany) and antimicrobial susceptibility testing (AST) was performed using the
170 automated system Vitek2®, (bioMérieux Marcy l'Etoile, France) and MicroScan panel
171 NBC44 (Beckman Coulter) according to European Committee on Antimicrobial
172 Susceptibility Testing (EUCAST) breakpoint.¹⁵ Isolates were tested for extended spectrum
173 beta-lactamases (ESBL) production using E-test ESBL stripes (bioMérieux) and the
174 double-disk synergy test with aztreonam and amoxicillin/clavulanic acid. Isolates having a
175 MIC > 1 mg/L to imipenem or meropenem and > 0.5 mg/L to ertapenem were confirmed
176 by PCR (OXA-48, VIM, KPC, NDM specific primers) with OXVIKPN® real time PCR
177 kit (Progenie Molecular, Spain).

178 Genetic relationships between isolates were determined by multilocus-sequence typing and
179 automated repetitive-sequence-based PCR in *Klebsiella pneumoniae* using the
180 DiversiLab® (bioMérieux) system.

181 *Outcome parameters*

182 Primary outcome was death within 30 days after the first positive CRE blood culture.
183 Relationship between death and BSI episode (directly related or not directly related) was
184 established by two independent investigators, by reviewing hospital medical records.

185 *Statistical analysis*

186 Categorical variables were presented as absolute frequencies and percentages. Continuous
187 variables were presented as the mean or median, with its standard deviation or ranges,
188 respectively. Categorical variables were compared using chi-square test or Fisher's Exact
189 test, as appropriate. Continuous variables were compared by Student's t test or Mann-
190 Whitney U test according to their distribution. Univariate analysis was conducted to
191 evaluate different possible factors related to mortality. The survival analysis was carried

192 out by means of the Kaplan-Meier analysis and "log-rank test" was performed to compare
193 survival functions. A two-tailed P value < 0.05 was considered statistically significant. All
194 statistical analysis was performed using SAS 9.3 (SAS Institute, Cary, NC, USA).

195 *Ethics*

196 HULP Institutional Review Board evaluated and approved the study protocol. All collected
197 data were anonymized. Given its observational retrospective design, written informed
198 consent was waived.

199

200 **Results**

201 *Clinical and epidemiological characteristics*

202 Of 2842 positive blood cultures in children during the study period, 928 (32.7%) were
203 Enterobacteriaceae and 38 (1.3%) were CRE isolates that met inclusion criteria (Table 1).
204 Most cases were detected between 2010 and 2015 (73.6%). Mean age was 2.2 years (DS
205 3.2, range 0-14.5) and patients were predominantly female (55.3%).

206 No community-acquired cases were detected. Twenty-nine (76.3%) cases were hospital-
207 acquired infections and 9 (23.7%) were related to healthcare.

208 In regard to underlying conditions, 20 patients (52.6%) had received a transplant. Solid
209 organ transplant was documented in 13 (9 liver, 3 multivisceral and 1 kidney), an allogenic
210 hematopoietic stem cell transplantation in 6 patients and 1 patient had received both
211 (multivisceral and allogeneic hematopoietic stem cell transplantation). Other medical
212 conditions were: heart disease (5/38, 13.2%), neurological (4/38; 10.5%), respiratory (4/38,
213 10.5%), urological (3/38, 7.9%), digestive (3/38, 7.9%) and malignancy (one hematologic
214 and one solid organ tumor). Fourteen (36.8%) patients were born prematurely.

215 At the time of bacteremia, 51.7% of patients with hospital-acquired disease were
216 hospitalized in intensive care units (8 in PICU, 7 in NICU), 41.4% in a medical ward and
217 6.9% were in a surgical ward (Post-Anesthesia Care Unit).

218 The rate of previous antibiotic exposure, indwelling devices and other possible risk factors
219 for CRE infection are shown in Table 2.

220 Regarding the source of bacteremia, the intestinal tract was found to be the most common
221 origin causing 11 cases (26.3%), followed by central venous catheter-related bacteremia in
222 8 (21.1%) and hepatobiliary origin in 6 (5.8%) patients. Three (7.9%) children had urinary
223 tract infection and one patient had a peritoneal catheter-related infection. Only one patient
224 had ventilator-associated pneumonia. The origin remained unknown in 8 (21.1%) cases.

225 As per severity of disease, 32 (84.2%) patients with CRE BSI met systemic inflammatory
226 response syndrome (SIRS) criteria of which 8 (21.1%) presented as septic shock.

227 *Microbiological results*

228 The isolated bacteria, resistance mechanisms and susceptibility to antimicrobials are shown
229 in Table 3.

230 *Treatment and outcomes*

231 Crude mortality within 30 days from onset of BSI was 18.4% (7/38). Death was considered
232 directly related to the BSI episode in 10.5% of total cases, based on clinical judgment.

233 Before antibiotic susceptibility test results, 10 (26.3%) children received microbiologically
234 inappropriate empiric therapy (no active antibiotic) while the remaining 28 (73.7%)
235 patients were treated with at least one active antibiotic. In 23 (60.5%) cases a carbapenem

236 was used before knowing antibiotic susceptibilities. Median duration of empiric treatment
237 was 3 days (IQR 2-5). Optimal early source control was performed in 23.7% (9/38).

238 Thirty-six (94.7%) patients received microbiologically appropriate targeted therapy and 15
239 of them (39.5%) were clinically adequately treated with at least two active antibiotics, at a
240 proper dosage and route according to the source of infection.

241 In univariate analysis, we found a significantly higher mortality rate in patients admitted to
242 neonatal and intensive care units at the time of BSI onset. Including one active antibiotic in
243 the empiric therapy showed to decrease mortality risk in a 92.4% compared to non-active
244 antibiotic (HR 0.076; IC 95% 0.012-0.494). There was no difference in survival depending
245 on meropenem MIC and neither between patients who received meropenem as empiric
246 therapy and those who not. Attending targeted treatment, we did not find differences when
247 monotherapy was used versus combination therapy and the use of meropenem did not
248 prove to improve survival either (Table 4, Figure 1).

249

250 **Discussion**

251 In the present study, we report 38 cases of CRE bacteremia in pediatric population. To the
252 best of our knowledge, this is the largest current pediatric cohort reported in Europe.

253 Novel agents (ceftazidime-avibactam, aztreonam-avibactam, cefiderocol, etc.) were not
254 available during the study period, so only classical therapeutic agents were used. VIM-type
255 metallo-beta-lactamases were the predominant resistance mechanism in our series, as they
256 were present in 35 of the 38 strains. These VIM-type enzymes were first discovered in
257 Europe in the 1990s and have been reported worldwide in the recent multidrug-resistant
258 Enterobacteriaceae crisis, although the Mediterranean basin and the Middle East are the
259 predominant areas.¹⁶ Most of our cases (73.6%) were detected between 2010 and 2015,

260 due to a VIM 1 *Klebsiella pneumoniae* ST- 54 outbreak during 2010 and an OXA-48
261 *Klebsiella pneumoniae* ST-11 outbreak in 2012. Antimicrobial stewardship program
262 initiatives in children emerged in 2014 in our hospital, primarily focused on PICU patients
263 so we only found one CRE BSI after 2015.

264 All episodes of infection in our study were either hospital-acquired or associated with
265 healthcare as in other similar series.^{3,17} Regarding risk factors of CRE BSI, we found that
266 those children who developed CRE BSI had multiple comorbidities, most of them (52.6%)
267 had received a transplant since our hospital is National Referral Hospital for pediatric
268 transplantation. Of note, 94.7% of patients were carriers of indwelling devices. In addition,
269 they often had exposure to carbapenems in the previous 6 months (50%).

270 The 30-day mortality rate in our study (18.4%) is not as high as compared with previous
271 reports, ranged from 18.5 to 52%.^{5,18-20} Grouping data from those reports and our cohort,
272 mortality rate is 31.8% in pediatric CRE bacteremia, although important differences
273 between series are obvious, including different resistance mechanisms or bacteremia
274 severity. For instance, our lower mortality rate could be related to the relatively low rate of
275 severe bacteremia in our series (21.1% had septic shock) and also to the fact that many
276 strains were susceptible to aminoglycosides (81.6%), offering therapeutic options. In India,
277 Nabarro et al. found a mortality rate of 52%, but resistance to aminoglycosides in their
278 cohort was up to 90%.⁵ In a recent study in Chinese pediatric population with
279 carbapenem-resistant *K.pneumoniae* BSI, mortality rate was similar than ours in relation to
280 low clinical severity and hematological malignancies predominance whose empirical
281 therapy used to be more effective in covering multidrug-resistant bacteria.¹⁸ In a meta-
282 analysis of carbapenem-resistant *K. pneumoniae* infections, mortality was not shown to be
283 lower in VIM-producing compared to KPC. Therefore it is unlikely that the VIM
284 predominant resistance mechanism in our cohort explains our lower mortality rate.²¹

285 We have found a relationship between increased 30 day-mortality and inadequate
286 empirical antibiotic therapy (no active agent), as was shown in previous studies.²² A recent
287 report by Lodise et al. has established that delayed appropriate therapy may be a more
288 important driver of outcomes than CRE itself.²³ However, Zhang et al. did not identify an
289 association between non-active empirical antibiotic agents and mortality in children.¹⁸ Of
290 note, 52.6% of patients in our cohort had been colonized or infected by a CRE before, as
291 systematic CRE colonization screening in our hospital is performed since 2010 in many
292 units. In adults, Girmenia et al. showed a rate of CRE infection in previously colonized-
293 patients of 10% for immunocompetent, 25% for those with neutropenia, 26% for auto-SCT
294 (stem cells transplant) and 39% for allo-SCT.²⁴ In our pediatric hospital, an infection rate
295 of 13% has been established in patients with previous VIM-type CRE colonization²⁵, but
296 from our knowledge no pediatric data has set which colonized children are at a higher risk
297 to develop an infection. As many patients in our cohort were previously CRE colonized
298 and active antibiotic in empiric therapy showed to decrease mortality risk in a 92.4%
299 compared to non-active antibiotic, antimicrobial stewardship guided antibiogram in
300 colonized stools from selected highly-risk patients might be an interesting strategy to
301 improve CRE BSI prognosis. However, rapid diagnostic testing aiming to reduce the time
302 to effective therapy in antimicrobial stewardship programs would be the most desirable
303 approach.²⁶

304 Patients admitted to neonatal units and to intensive care units also had significant higher
305 mortality rates in our cohort. Of note, in our survival analysis, there was no evidence of
306 higher mortality in patients with isolated *Klebsiella* spp. strains. No source of infection
307 showed relation to mortality either. Relationship between meropenem MIC and increased
308 mortality has previously been described in adults and Nabarro and Zhang also found
309 statistically increased mortality rate in pediatric patients with CRE BSI with a meropenem

310 MIC > 8mg/L.^{5,18} Nevertheless, in our cohort meropenem MIC > 8 was not predictive of
311 higher mortality. Empiric antibiotic therapy that included meropenem was also no
312 protective in Zhang's et al. report. Regarding the use of aminoglycosides as empiric
313 treatment, we did not find differences in mortality either.

314 In adults, retrospective observational studies have suggested improved survival in patients
315 receiving combinations of two or more in vitro active antibiotics, mostly among patients
316 with a high probability of death.⁶ These data have been extrapolated to children with a
317 number of authors suggesting use of combination antibiotics in CRE.⁸ The few pediatric
318 series so far show controversy in this aspect. In our study, targeted treatment with
319 combinations of two or more active agents did not lead to higher survival than
320 monotherapy, as has been shown in a recent clinical trial in adults, where combination
321 therapy was not superior to monotherapy.²⁷ However, most infections in Paul et al. trial
322 (77%) were caused by *Acinetobacter baumannii* so CRE might have been under-
323 represented. The inclusion of meropenem in the targeted therapy also showed no survival
324 improvement in our cohort.

325 Our study has some limitations. It is a retrospective study of a single cohort from just one
326 center so the sample size is limited, although it is the largest pediatric series reported in
327 Europe so far. This may have influenced the statistical power to identify risk factors and
328 predictors of mortality. Moreover, the high proportion of VIM-producing
329 Enterobacteriaceae in our cohort leads to results that may not be representative for all
330 CRE. Regarding surveillance analysis, our low mortality rate decreases the reliability of
331 results and we have not used severity scores. Nevertheless, given the scarcity of literature
332 on this important subject, mostly in Western Europe, we believe it offers useful insights
333 into the management of CRE BSI in children.

334 The findings of this study suggest CRE BSI are a growing problem in pediatric patients
335 with comorbidities and underlying devices. The independent factor more related to 30-day
336 mortality in our cohort was success in empiric treatment with at least one active antibiotic.
337 Antimicrobial stewardship strategies focusing on the adequacy of empiric therapy are
338 needed in CRE BSI. Combination antibiotic targeted treatment and a low Meropenem MIC
339 were not related to improved survival in our cohort but sample size might limit these
340 findings.

341

342 **Funding**

343 This work was not economical supported by any institution.

344

345 **Transparency declarations**

346 María Fátima Ara-Montojo and Luis Escosa-García contributed equally to this article and
347 both should be considered first author. We have nothing to declare.

348

349

350

351

352

353

354 **Bibliography**

- 355 1. Montagnani C, Prato M, Scolfaro C, et al. Carbapenem-resistant enterobacteriaceae
356 infections in children: An Italian retrospective multicenter study. *Pediatr Infect Dis*
357 *J.* 2016;35(8):862-868. doi:10.1097/INF.0000000000001188
- 358 2. Logan LK, Renschler JP, Gandra S, Weinstein RA LR. Carbapenem-Resistant
359 Enterobacteriaceae in Children, United States, 1999–2012. *Emerg Infect Dis.*
360 2015;21(11):2014-2021. doi:10.3201/eid2111.150548
- 361 3. Díaz A, Ortiz DC, Trujillo M, Garcés C, Jaimes F, Restrepo AV. Clinical
362 characteristics of carbapenem-resistant *Klebsiella pneumoniae* infections in ill and
363 colonized children in Colombia. *Pediatr Infect Dis J.* 2016;35(3):237-241.
364 doi:10.1097/INF.0000000000000987
- 365 4. Chiotos K, Tamma PD, Flett KB, et al. Multicenter study of the risk factors for
366 colonization or infection with carbapenem-resistant Enterobacteriaceae in children.
367 *Antimicrob Agents Chemother.* 2017;61(12):1-9. doi:10.1128/AAC.01440-17
- 368 5. Nabarro LEB, Shankar C, Pragasam AK, et al. Clinical and Bacterial Risk Factors
369 for Mortality in Children with Carbapenem-resistant Enterobacteriaceae
370 Bloodstream Infections in India. *Pediatr Infect Dis J.* 2017;36(6):e161-e166.
371 doi:10.1097/INF.0000000000001499
- 372 6. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate
373 combination therapy on mortality of patients with bloodstream infections due to
374 carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective
375 cohort study. *Lancet Infect Dis.* 2017;17(7):726-734. doi:10.1016/S1473-
376 3099(17)30228-1

- 377 7. Daikos GL, Tsaousi S, Tzouveleki LS, et al. Carbapenemase-producing *Klebsiella*
378 pneumoniae bloodstream infections: Lowering mortality by antibiotic combination
379 schemes and the role of carbapenems. *Antimicrob Agents Chemother.*
380 2014;58(4):2322-2328. doi:10.1128/AAC.02166-13
- 381 8. Hsu AJ, Tamma PD. Treatment of multidrug-resistant gram-negative infections in
382 children. *Clin Infect Dis.* 2014;58(10):1439-1448. doi:10.1093/cid/ciu069
- 383 9. Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of Carbapenem-Resistant
384 Enterobacteriaceae Infections in Children. 2019;(Xx Xxxx):1-11.
385 doi:10.1093/jpids/piz085
- 386 10. Aguilera-Alonso D1, Escosa-García L2, Saavedra-Lozano J3, Cercenado E4 B-AF.
387 Carbapenem-Resistant Gram-Negative Bacterial Infections in Children. *Antimicrob*
388 *Agents Chemother.* 2020;64(3). doi:10.1128/AAC.02183-19
- 389 11. Centers for Disease Control and Prevention. CDC. Facility Guidance for Control of
390 Carbapenem-resistant Enterobacteriaceae (CRE). *Natl Cent Emerg Zoonotic Infect*
391 *Dis.* 2014;(November):24.
392 https://www.osha.gov/SLTC/ebola/control_prevention.html.
- 393 12. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP et al.
394 Health care--associated bloodstream infections in adults: a reason to change the
395 accepted definition of community-acquired infections. *Ann Intern Med [Internet].*
396 2002;137(10):791-797. doi:10.7326/0003-4819-137-10-200211190-00007
- 397 13. Glodstein, B., Giroir, B., & Randolph A. International pediatric sepsis consensus
398 conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatr Crit*
399 *Care Med.* 2005;6(1):96.

- 400 14. FA M. IDSA guidelines for the diagnosis and management of intravascular catheter-
401 related bloodstream infection. *Clin Infect Dis*. 2009;49(11):1770-1771.
402 doi:10.1086/648112
- 403 15. EUCAST Breakpoint tables v 8.1. http://www.eucast.org/clinical_breakpoints/.
404 Published 2018.
- 405 16. Cornaglia G, Giamarellou H, Rossolini GM. Metallo- β -lactamases: A last frontier
406 for β -lactams? *Lancet Infect Dis*. 2011;11(5):381-393. doi:10.1016/S1473-
407 3099(11)70056-1
- 408 17. Malande OO, Du Plessis A, Rip D, Bamford C, Eley B. Invasive carbapenem-
409 resistant Enterobacteriaceae infection at a paediatric hospital: A case series. *South*
410 *African Med J*. 2016;106(9):877. doi:10.7196/SAMJ.2016.v106i9.11028
- 411 18. Zhang Y, Guo LY, Song WQ, Wang Y, Dong F, Liu G. Risk factors for
412 carbapenem-resistant *K. pneumoniae* bloodstream infection and predictors of
413 mortality in Chinese paediatric patients. *BMC Infect Dis*. 2018;18(1):1-10.
414 doi:10.1186/s12879-018-3160-3
- 415 19. Maltezou HC, Kontopidou F, Katerelos P, Daikos G, Roilides E, Theodoridou M.
416 Infections caused by carbapenem-resistant gram-negative pathogens in hospitalized
417 children. *Pediatr Infect Dis J*. 2013;32(4):151-154.
418 doi:10.1097/INF.0b013e3182804b49
- 419 20. Ozsurekci Y, Aykac K, Cengiz AB, et al. Bloodstream infections in children caused
420 by carbapenem-resistant versus carbapenem-susceptible gram-negative
421 microorganisms: Risk factors and outcome. *Diagn Microbiol Infect Dis*.
422 2017;87(4):359-364. doi:10.1016/j.diagmicrobio.2016.12.013

- 423 21. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients
424 infected with carbapenem-resistant *Klebsiella pneumoniae*. *Ann Clin Microbiol*
425 *Antimicrob*. 2017;16(1):1-12. doi:10.1186/s12941-017-0191-3
- 426 22. Micozzi A, Gentile G, Minotti C, et al. Carbapenem-resistant *Klebsiella pneumoniae*
427 in high-risk haematological patients: Factors favouring spread, risk factors and
428 outcome of carbapenem-resistant *Klebsiella pneumoniae* bacteremias. *BMC Infect*
429 *Dis*. 2017;17(1):1-12. doi:10.1186/s12879-017-2297-9
- 430 23. Lodise T, Sciences H, Bonine NG, et al. Antimicrobial Resistance or Delayed
431 Appropriate Therapy—Does One Influence Outcomes More Than the Other among
432 Patients with Serious Infections due to Carbapenem-Resistant Versus Carbapenem-
433 Susceptible Enterobacteriaceae? *Open Forum Infect Dis*. 2019;ofz194(Major
434 Article).
- 435 24. Girmenia C, Rossolini GM, Piciocchi A, et al. Infections by carbapenem-resistant
436 *Klebsiella pneumoniae* in SCT recipients: A nationwide retrospective survey from
437 Italy. *Bone Marrow Transplant*. 2015;50(2):282-288. doi:10.1038/bmt.2014.231
- 438 25. González-rubio R, Parra-blázquez D, San-juan-sanz I, Ruiz-carrascoso G, Gallego
439 S, Escosa-garcía L. Original Evolución de la incidencia de pacientes con
440 colonización e infección por bacterias productoras de carbapenemasas VIM en un
441 hospital pediátrico en España. 2019;32(1):60-67.
- 442 26. Timbrook TT, Morton JB, Mcconeghy KW, Caffrey AR, Mylonakis E, Laplante
443 KL. The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in
444 Bloodstream Infections □: A Systematic Review and Meta-analysis. 2017;64:15-23.
445 doi:10.1093/cid/ciw649

446 27. Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus
447 meropenem for treatment of severe infections caused by carbapenem-resistant
448 Gram-negative bacteria: an open-label, randomised controlled trial. *Lancet Infect*
449 *Dis.* 2018;18(4):391-400. doi:10.1016/S1473-3099(18)30099-9

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

	Age at admission	Sex	Department	Bacteremia	Microorganism	Source	Carbapenem Resistance	ESBL	Exitus at 30th day	Sepsis /shock	Days from admission to BSI	Days from BSI to discharge / death	Empirical Treatment (ACTIVE AGAINST GRAM NEGATIVE BACTERIA)	Targeted Treatment
1	5 m	F	Post-anesthesia Care Unit	HA	<i>K. pneumoniae</i>	Gut	VIM	☐	A	☐	106	392	Meropenem	Meropenem + Amikacin + Ciprofloxacin
2	4 m	M	Post-anesthesia Care Unit	HA	<i>K. pneumoniae</i>	Catheter related	VIM		†		22	3	Meropenem + Amikacin	Meropenem + Amikacin
3	4 y	M	Hepatology Ward	HCA	<i>K. oxytoca</i>	Hepatobiliar	VIM		A	☐	0	21	Cefotaxime	Meropenem + Amikacin
4	5 m	M	PICU	HA	<i>C. freundii</i>	Hepatobiliar	VIM		A		17	95	Meropenem + Amikacin	Meropenem + Amikacin
5	14 m	F	Hepatology Ward	HA	<i>K. pneumoniae</i>	Hepatobiliar	VIM	☐	A	☐	110	152	Meropenem	Meropenem + Amikacin
6	3 y	F	PICU	HA	<i>K. pneumoniae</i>	Hepatobiliar	VIM	☐	A	☐	51	30	Gentamicin + Ciprofloxacin	Ciprofloxacin
7	3 m	M	PICU	HA	<i>K. pneumoniae</i>	Catheter related	VIM		A	☐	29	5	None	Amikacin
8	3 y	F	Hepatology Ward	HA	<i>S. ureilytica</i>	Gut	VIM	☐	A		126	23	Cefepime + Colistin	Ciprofloxacin
9	4 m	M	Neonatal Unit	HA	<i>K. pneumoniae</i>	Unknown	VIM		†	☐	109	22	Meropenem + Amikacin	Meropenem + Amikacin
10	2 m	F	Neonatal Unit	HA	<i>K. pneumoniae</i>	Unknown	Porins resistance	☐	A	☐	355	70	Meropenem	Meropenem + Amikacin
11	18 d	M	Neonatal Unit	HA	<i>K. pneumoniae</i>	Gut	VIM		†	☐	2	3	Cefotaxime + Meropenem	
12	59 d	F	Neonatal Unit	HA	<i>K. pneumoniae</i>	Unknown	OXA-48	☐	†	☐	59	22	Cefotaxime	Amikacin
13	5 m	M	Neonatal Unit	HA	<i>E. cloacae</i>	Gut	VIM		A	☐	150	22	Amikacin	Amikacin
14	75 d	M	Neonatal Unit	HA	<i>K. pneumoniae</i>	UTI	OXA-48	☐	A	☐	75	226	Meropenem	Meropenem + Amikacin
15	6 m	M	PICU	HA	<i>S. marcescens</i>	Pulmonary	VIM		A		4	18	Cefotaxime	Cefotaxime + Gentamicin + Aztreonam
16	17 m	F	Haemato-oncology Ward	HA	<i>S. marcescens</i>	Unknown	VIM		A	☐	8	17	Meropenem + Amikacin	Meropenem + Amikacin
17	7 m	F	Haemato-oncology Ward	HA	<i>k. pneumoniae</i>	Unknown	VIM		A		21	375	Meropenem + Amikacin	Meropenem + Amikacin
18	14 y	M	Haemato-oncology Ward	HA	<i>E. cloacae</i>	Unknown	VIM	☐	A	☐	60	31	Cefepime + Meropenem	Amikacin + Ciprofloxacin
19	10 y	F	Haemato-oncology Ward	HA	<i>E. cloacae</i>	Gut	VIM		A	☐	36	17	Meropenem + Cefepime	Meropenem + Ciprofloxacin
20	3 y	M	Haemato-oncology Ward	HA	<i>K. oxytoca</i>	Gut	VIM	☐	A		1	7	Cefixime, Cefotaxime	Ciprofloxacin
21	7 m	M	General Paediatrics Ward	HA	<i>K. pneumoniae</i>	Catheter related	VIM	☐	A	☐	19	21	Meropenem	Ciprofloxacin
22	8 m	F	PICU	HA	<i>K. pneumoniae</i>	Peritonitis	VIM	☐	A	☐	143	4	Meropenem	Meropenem + Colistin
23	4 y	F	Haemato-oncology Ward	HA	<i>E. cloacae</i>	Unknown	VIM		A	☐	60	42	Cefepime + Amikacin	Ciprofloxacin + Amikacin
24	4 y	M	Gastroenterology Ward	HCA	<i>E. coli</i>	Catheter related	VIM		A	☐	0	38	Meropenem + Amikacin	Meropenem + Amikacin
25	2 y	M	Nephrology Ward	HA	<i>K. pneumoniae</i>	UTI	VIM	☐	A	☐	6	12	Amikacin + Ceftazidime	Amikacin + Ciprofloxacin
26	2 y	M	Hepatology Ward	HA	<i>E. cloacae</i>	Hepatobiliar	VIM		A	☐	48	176	Meropenem + Amikacin	Amikacin + Ciprofloxacin
27	2 y	F	PICU	HA	<i>E. cloacae</i>	Pulmonary	VIM		A	☐	26	45	Meropenem + Amikacin	Meropenem + Amikacin + Ciprofloxacin
28	10 m	F	Gastroenterology Ward	HCA	<i>E. aerogenes</i>	Catheter related	VIM		A	☐	1	22	Meropenem + Gentamicin	Gentamicin + Aztreonam
29	6 m	M	PICU	HA	<i>K. pneumoniae</i>	Hepatobiliar	VIM	☐	A	☐	63	64	Meropenem + Colistin	Colistin + Fosfomycin

30	4 y	M	Gastroenterology Ward	HCA	<i>K. pneumoniae</i>	Catheter related	VIM		A	☒	0	50	Amikacin	Amikacin + Aztreonam
31	15 m	M	Nephrology Ward	HCA	<i>K. pneumoniae</i>	Peritoneal dialysis catheter	VIM		A	☒	1	8	Meropenem + Amikacin	Amikacin + Aztreonam
32	16 y	M	PICU	HCA	<i>K. pneumoniae</i>	Gut	VIM		†	☒	4	2	Cefepime + Amikacin + Colistin	Colistin + Aztreonam + Fosfomycin
33	4 y	M	General Pediatrics Ward	HCA	<i>K. pneumoniae</i>	Gut	VIM		A	☒	0	16	Meropenem + Amikacin	Amikacin
34	22 m	M	Haemato-oncology Ward	HA	<i>K. pneumoniae</i>	Catheter related	VIM	☒	A	☒	226	41	Meropenem	Imipenem + Amikacin + Ciprofloxacin
35	2 y	F	Haemato-oncology Ward	HCA	<i>K. pneumoniae</i>	Catheter related	VIM		A	☒	0	14	Cefepime	Amikacin + Ciprofloxacin
36	9 y	F	PICU	HA	<i>K. oxytoca</i>	Gut	VIM		†	☒	50	2	Meropenem + Amikacin	Meropenem + Ciprofloxacin + Colistin
37	10 m	F	Emergency Department	HCA	<i>K. oxytoca</i>	UTI	VIM		A	☒	-1	5	Amikacin + Fosfomycin	Cotrimoxazole
38	5 m	F	Neonatal Unit	HA	<i>S. marcescens</i>	Unknown	VIM		†	☒	175	30	Ciprofloxacin	Ciprofloxacin

467

468 **TABLE 1.** Clinical features of patients with bacteremia due to CRE. Months (m), female (F), hospital-
469 acquired (HA), alive (A), exitus (†), male (M), years (y), health care associated (HCA), days (d), urinary tract
470 infection (UTI).

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

Risk factor	N (%)	491
		Total N: 38
Any antibiotic exposure (30 previous days)	32 (84.2)	492
Cephalosporin exposure (30 previous days)	19 (50)	493
Carbapenem exposure (6 previous months)	19 (50)	
Admission to a unit with previous CRE cases (12 previous months)	14 (36.8)	494
Previous colonization or infection by CRE	20 (52.6)	495
Surgery	18 (47.4)	496
Central venous catheter	35 (92.1)	
Urinary catheter	20 (52.6)	497
Drainage tube	12 (31.5)	498
Parenteral nutrition	26 (77)	
Mechanical ventilation	18 (47.4)	499
Neutropenia	5 (13.2)	500
Renal failure	9 (23.7)	

501

502 **TABLE 2.** Risk factors related to CRE bacteremia.

503

504

505

506

507

508

509

510

511

512

513

514

Strain		AZT	ERT	IMI	MER	COL	AK	CIP	TYG	FOS
	<i>K. pneumoniae</i> VIM (18)	Range MIC	≤1 - >8	1 ->1	2 - >8	≤1 ->8	≤0.5->4	≤2 ->32	≤0,5 ->2	≤1 - >4
	S (%)	50	0	11.1	44.4	83.3	72.2	61.1	77.7	83.3
<i>K. pneumoniae</i> OXA-48 ESBL (2)	Range MIC	>16	>1	2-8	2-8	≤0.5	≤2	>2	4	>64
	S (%)	0	0	50	50	100	100	0	0	0
<i>K. pneumoniae</i> ESBL (1)	MIC	>16	>1	8	8	≤0.5	≤2	>2	≤1	≤16
	S (%)	0	0	0	0	100	100	0	100	100
<i>E. cloacae</i> VIM (6)	Range MIC	≤1 - >8	≤0.5->1	4 - >8	≤1 ->8	≤0.5 ->4	≤2	≤0.5 - 1	≤1	≤16
	S (%)	66.6	50	16.6	50	66.6	100	66.6	100	83.3
<i>K. oxytoca</i> VIM (4)	Range MIC	≤1->32	>32	≤1->8	≤1->8	≤0.5	≤2->32	≤0,5	≤1	≤32->64
	S (%)	50	0	25	50	100	75	100	100	25
<i>S. marcescens</i> VIM (3)	Range MIC	≤1	>1	>8	>8	>2	≤2	≤0,5	≤1	≤32->64
	S (%)	100	0	0	0	0	100	100	66.6	66.6
<i>E.coli</i> VIM (1)	MIC	≤1	1	8	8	≤0.5	≤2	≤0.5	≤1	32
	S I R	S	I	I	I	S	S	S	S	S
<i>C. freundii</i> VIM (1)	MIC	≤1	>1	>8	>8	≤0.5	≤2	≤0.5	≤1	≤16
	S I R	S	R	R	R	S	S	S	S	S
<i>S. ureilytica</i> VIM (1)	MIC	>8	1	>8	2	>4	≤2	≤0,5	≤1	32
	S I R	R	I	R	S	R	S	S	S	S
<i>E. aerogenesa</i> VIM (1)	MIC	>8	1	>8	2	>4	≤2	≤0,5	≤1	32
	S I R	R	I	R	S	R	S	S	S	S
ALL (38)	S (%)	55.3	7.9	13.2	39.5	73.6	84.2	68.4	81.6	71.1
	I (%)	2.6	7.9	36.8	34.2	---	---	---	7.9	---
	R (%)	42.1	84.2	50	26.3	26.3	15.8	31.6	10.5	28.9

515

516 **TABLE 3.** Resistance of strains to antimicrobials agents. "MIC" is the Minimum Inhibitory
517 Concentration acquired in mg/L; "Range MIC" is the range of Minimum Inhibitory Concentration; "S" stands
518 for susceptible; "I" for intermediate and "R" for resistant, as interpreted according to the EUCAST V 6.0
519 guidelines. "AZT" for aztreonam, "ERT" for ertapenem, "IMI" for imipenem, "MER" for meropenem, "COL"
520 for colistin, "AK" for amikacin, "CIP" for ciprofloxacin, "TYG" for tygeciline, "FOS" for fosfomycin.

521


522

Variable	Survived N=31 (%)	Died N=7 (%)	Hazard ratio (95% CI)	P
Median Age (months)	17.64	4.32		
Male (%)	54.84	57.14		
Klebsiella isolated	19 (61.29)	6 (85.71)		NS
Source of infection:				
Intestinal or hepatobiliary tracts	13 (41.94)	3 (42.86)		NS
Catheter-related	7 (22.58)	1 (14.29)		NS
Urinary tract	3 (9.68)	0 (0)		NS
Pulmonary	2 (6.45)	0 (0)		NS
Peritoneal catheter	1 (3.23)	0 (0)		NS
Unknown	5 (16.13)	3 (42.86)		NS
Neonatal unit admission	3 (9.68)	4 (57.14)	0.197 (0.111-0.956)	0.017
Intensive care unit admission	10 (32.26)	6 (85.71)	0.13 (0-0.984)	0.024
Presentation as sepsis	26 (83.87)	6 (85.71)		NS
Presentation as septic shock	5 (16.13)	3 (42.86)		NS
Meropenem MIC >8 mg/L	8 (25.81)	2 (28.57)		NS
Optimal early source control	8 (25.81)	1 (14.29)		NS
No-active antibiotic in empiric therapy	6 (19.35)	4 (57.14)	0.076 (0.012-0.494)	0.001
Meropenem in empiric therapy	19 (61.29)	4 (57.14)		NS
Aminoglycoside in empiric therapy	15 (48.39)	4 (57.14)		NS
Non-clinically adequately or improvable target therapy	19 (61.29)	3/6 (50)*		NS
Monotherapy in target treatment	16 (51.61)	3/6 (50)*		NS
Meropenem in target therapy	14 (45.16)	4/6 (66.66)*		NS

523

524 **TABLE 4.** Univariate analysis of risk factor associated with 30-day mortality. The survival analysis was
525 carried out by means of the Kaplan-Meier analysis and "log-rank test" was performed to compare the

526 survival functions. A two-tailed P value < 0.05 was considered statistically significant. Non-significant (NS).
527 *One patient excluded because of death before knowing antibiogram.



536 **FIGURE 1.** Kaplan-Meier curves of different factors and survival at 30 days in patients with CRE
537 bacteremia. Non-significant (NS); Minimum Inhibitory Concentration (MIC)